Platelet-Rich Plasma (PRP) Therapy — Evidence-Based Treatment Guide — Cost, Top Hospitals & Success Rates | MyMedicPlus

Platelet-rich plasma (PRP) is an autologous biological concentrate derived from the patient's own blood, enriched in platelets to concentrations 3–5 times above baseline (targeting 1–1.5 million platelets per microlitre). The therapeutic rationale rests on the dense payload of bioactive molecules stored in platelet alpha-granules, including growth factors, cytokines, and adhesion proteins that collectively orchestrate tissue repair, angiogenesis, and cellular proliferation.

PRP was first described clinically in the 1990s in oral and maxillofacial surgery, and has since expanded across orthopaedics, sports medicine, dermatology, wound care, ophthalmology, urology, and aesthetics. Its appeal lies in the autologous nature — using the patient's own blood eliminates concerns about immune rejection, disease transmission, or donor shortages.

Preparation involves drawing 15–60 mL of venous blood into anticoagulant (sodium citrate or acid-citrate-dextrose) tubes, then separating components via centrifugation. A single-spin protocol separates red cells from plasma; a double-spin protocol further concentrates platelets into the buffy coat layer. The resulting PRP is then activated (using thrombin, calcium chloride, or left unactivated) and injected locally into the target tissue.

Despite growing clinical adoption, PRP remains characterised by significant preparation heterogeneity — no universal manufacturing standard exists. Variables include centrifuge speed and time, leukocyte content (leukocyte-rich vs. leukocyte-poor), activation method, platelet dose, injection volume, and injection frequency. This heterogeneity is the principal reason randomised controlled trial results are inconsistent and cross-study comparison is methodologically challenging. Standardisation systems such as MARSPILL and Mishra classification have been proposed but are not universally adopted.

PRP has been investigated across a broad spectrum of clinical conditions, with evidence strength varying considerably by indication:

• Knee Osteoarthritis (OA): The most extensively studied musculoskeletal PRP indication. PRP injections aim to reduce synovial inflammation, slow cartilage degradation, and improve joint lubrication. The RESTORE trial (2021, NEJM Evidence) found PRP non-inferior to hyaluronic acid (HA) for pain and function at 12 months, though neither was significantly superior to placebo. Earlier single-centre RCTs had been more favourable to PRP, highlighting how trial design affects outcomes.
• Tendinopathy: Chronic lateral epicondylitis (‘tennis elbow’), patellar tendinopathy, Achilles tendinopathy, and rotator cuff tendinopathy have been treated with PRP injections. TGF-β and PDGF within PRP stimulate tenocyte proliferation and extracellular matrix remodelling. Systematic reviews show modest-to-moderate benefit over corticosteroid injections at 3–6 months, particularly for lateral epicondylitis.
• ACL Augmentation: PRP has been used intraoperatively to accelerate tendon graft-to-bone healing and reduce graft tunnel widening in anterior cruciate ligament reconstruction. Evidence supports improved graft maturation on MRI, though functional superiority over standard reconstruction is less established.
• Androgenetic Alopecia (Male and Female Pattern Hair Loss): PRP scalp injections aim to stimulate dormant hair follicles via PDGF, VEGF, and IGF-1, promoting angiogenesis around follicular units and extending anagen phase. The International Society of Hair Restoration Surgery (ISHRS) systematic review (2019) found PRP significantly improved hair density, diameter, and growth rate in androgenetic alopecia, though evidence quality remained moderate.
• Chronic Wounds: Diabetic foot ulcers, venous leg ulcers, and pressure injuries that fail to heal with standard care have been treated with topical or intralesional PRP. Growth factors such as PDGF-BB and EGF stimulate granulation tissue formation, epithelialisation, and angiogenesis. A 2019 Cochrane review found low-certainty evidence suggesting PRP may improve complete wound healing compared to standard care alone.
• Sexual Medicine and Aesthetics: PRP has been marketed for erectile dysfunction, female sexual dysfunction, facial rejuvenation (‘vampire facial’), and scar revision — areas with limited high-quality evidence and requiring careful patient counselling.

PRP therapy is broadly accessible to most adults, but patient selection optimises safety and efficacy. Eligibility assessment should include a review of the underlying condition, prior treatment response, haematological status, and expectations.

General eligibility criteria:

• Adults with confirmed diagnosis of an indication where PRP has meaningful clinical evidence (knee OA, tendinopathy, androgenetic alopecia, chronic wounds)
• Failure or inadequate response to at least one conventional treatment (e.g., physiotherapy for tendinopathy, minoxidil for hair loss, HA injections for knee OA)
• Haemoglobin above 11 g/dL and platelet count above 100 × 10⁹/L to yield an adequate PRP concentrate
• No active infection at the injection site or systemic sepsis
• No active malignancy (particularly haematological malignancies), as growth factors may theoretically stimulate tumour cells

Contraindications:

• Platelet dysfunction disorders (Glanzmann thrombasthenia, Bernard-Soulier) — platelets cannot be adequately activated
• Hypofibrinogenaemia or severe coagulation factor deficiency
• Anaemia with haemoglobin below 10 g/dL (insufficient baseline platelet yield)
• Current antiplatelet therapy (aspirin, clopidogrel, NSAIDs) — ideally paused 5–7 days before PRP collection if clinically safe
• Corticosteroid injection at the target site within 4–6 weeks (steroids impair platelet aggregation and growth factor release)

Sport eligibility: Athletes governed by WADA-signatory organisations should note that intra-articular PRP injections are prohibited in competition without a Therapeutic Use Exemption (TUE). Subcutaneous and intramuscular injections are currently permitted. WADA periodically reviews this classification.

Expectation management: Patients should understand that PRP does not halt structural disease progression in OA or reverse advanced tissue loss, and that multiple sessions (typically 2–3) spaced 4–6 weeks apart are usually required before assessing response.

Blood Collection: 15–60 mL of peripheral venous blood is drawn into ACD-A or sodium citrate anticoagulant tubes immediately before preparation. Larger volumes yield more PRP and higher platelet doses, which matters particularly for large joint injections or scalp treatments.

Centrifugation Protocol: The standard double-spin method involves a first spin (soft spin, ~1,500–2,000 rpm for 10 minutes) to separate red blood cells from platelet-rich and platelet-poor plasma. The supernatant is then subjected to a second spin (hard spin, ~2,500–3,000 rpm for 15 minutes) to pellet platelets from platelet-poor plasma. The resulting PRP concentrate in the pellet is resuspended in a small volume (2–8 mL depending on indication).

Leukocyte Content: Leukocyte-rich PRP (LR-PRP) retains neutrophils and monocytes, which may be beneficial in infected or chronic wounds (antimicrobial properties, macrophage-mediated remodelling) but may worsen synovial inflammation when injected intra-articularly. Leukocyte-poor PRP (LP-PRP) is generally preferred for intra-articular applications including knee OA. Neither has been definitively proven superior across all indications.

Activation Methods: PRP can be activated exogenously (with bovine thrombin + calcium chloride, producing a PRP gel) or endogenous activation is triggered upon contact with tissue collagen at the injection site. Non-activated PRP is increasingly preferred to avoid theoretical immune sensitisation to bovine thrombin.

Clinical Protocols by Indication:

• Knee OA: 3–5 mL LP-PRP, intra-articular injection; 1–3 sessions at 4-week intervals; ultrasound guidance recommended for precision
• Tendinopathy: 2–4 mL LR-PRP, intratendinous or peritendinous injection; 1–3 sessions; fenestration of the tendon may enhance uptake
• Androgenetic Alopecia: 3–7 mL PRP injected into the scalp in a grid or nappage pattern at the dermal-subcutaneous junction; 3 monthly sessions, then quarterly maintenance
• Chronic Wounds: PRP gel applied topically or injected intradermally around wound margins; dressings changed every 3–5 days; course of 4–8 applications over 4–8 weeks

Commercial Systems: Standardised FDA-cleared PRP preparation kits (e.g., Arthrex ACP, Regen Lab PRP, Harvest Technologies) provide more consistent platelet concentrations than manual centrifugation and are increasingly used in clinical and sports medicine settings.

PRP offers a biologically rational, minimally invasive, autologous approach to tissue repair, with an overall favourable safety profile. Evidence strength varies substantially by indication.

Musculoskeletal outcomes: For lateral epicondylitis, multiple RCTs show PRP outperforms corticosteroid injection at 3–6 months for pain and function, though both return to similar levels by 12 months. For chronic patellar tendinopathy, a 2021 systematic review found PRP superior to dry needling and comparable to volume injection at 6 months. For knee OA, early single-centre RCTs were strongly positive; the large multicentre RESTORE trial (248 patients) showed PRP equivalent — but not superior — to HA at 12 months using KOOS total score, important for setting realistic patient expectations.

Hair restoration: In androgenetic alopecia, an ISHRS systematic review of 19 studies found PRP increased hair density by a mean of 33.6 hairs/cm², terminal hair diameter by 25–40%, and hair growth rate significantly versus controls. The treatment was effective in both male and female pattern hair loss. Benefits appear most pronounced in patients with Norwood-Hamilton scale grades II–IV (male) and Ludwig I–II (female).

Wound healing: In diabetic foot ulcers, PRP adjunct therapy has shown improved complete healing rates at 12–20 weeks compared to standard wound care in multiple RCTs, with particular benefit in patients with previously stalled healing. PDGF-BB within PRP mirrors the mechanism of becaplermin (recombinant PDGF gel), a licensed wound healing agent.

ACL reconstruction: PRP applied at the graft-tunnel interface has been associated with significantly better graft maturation (reduced signal-to-noise ratio on MRI) at 3 months and reduced tunnel widening on CT at 6 months in several RCTs, potentially indicating faster biological integration and earlier return to sport.

General advantages: Autologous origin eliminates infection transmission risk. Procedure is well-tolerated with minimal anaesthesia. Can be performed as an outpatient or clinic procedure without theatre access.

PRP is generally considered safe given its autologous nature, but clinicians and patients should be aware of the following risks and limitations.

Local injection-site reactions: Pain at the injection site is common — often more intense than corticosteroid injection — due to the local inflammatory response induced by growth factors, particularly in LR-PRP preparations. Post-injection flare (24–72 hours of increased pain and local swelling) occurs in up to 20–30% of musculoskeletal injections. Cold packs and oral paracetamol are recommended; NSAIDs should be avoided as they may blunt the platelet-mediated healing response.

Infection risk: Although low, improper aseptic technique during blood collection or injection can introduce infection. Strict sterile technique (surgical preparation, sterile gloves, draping) is mandatory. No cases of systemic infection from PRP have been reported in large series when standard precautions are observed.

Failure to respond: Approximately 30–40% of patients do not experience clinically meaningful benefit from PRP for musculoskeletal indications. Non-response is more common in advanced structural disease (Kellgren-Lawrence grade IV OA), prolonged chronicity of tendinopathy (>24 months), heavy smokers (reduced platelet function), and patients on chronic antiplatelet therapy.

Standardisation limitations: The greatest limitation of PRP is the absence of a universal preparation and dosing standard. Published trials use vastly different centrifugation protocols, platelet concentrations, leukocyte content, activation methods, and injection volumes — making it difficult to attribute outcomes specifically to PRP versus technique or placebo effect. The 2021 RESTORE trial highlighted this, showing no superiority over HA or saline in a rigorously controlled design.

WADA prohibition: Intra-articular PRP injections are banned in competition by WADA. Athletes must obtain TUE prior to intra-articular use during competition periods. Non-compliant use can result in sanctions.

Cost vs. evidence gap: PRP injections are rarely covered by insurance in most countries and are often self-funded at substantial cost, creating an affordability and equity concern relative to the current evidence base, particularly given RESTORE trial results.

Follow-up after PRP therapy depends on the indication, number of sessions planned, and treatment goals. Structured reassessment helps identify responders, avoid unnecessary repeated injections in non-responders, and manage expectations.

Musculoskeletal follow-up: Patients should be reviewed at 4–6 weeks after each injection to assess pain using validated scoring tools (KOOS for knee, DASH for elbow, VISA-P for patella). If improvement is documented, a second session may be scheduled. If no meaningful improvement is noted after two sessions, PRP is unlikely to benefit this patient and alternative treatments should be explored. Functional physiotherapy should be integrated alongside PRP for tendinopathy to address biomechanical contributors — PRP alone without rehabilitation is generally less effective.

Hair loss follow-up: Photographic assessment and trichoscopy (dermoscopy of scalp) at baseline and 3 months after the final session provide objective documentation of response. Hair density and diameter measurements using TrichoScan or FotoFinder are used in research settings and may be available in specialist trichology clinics. Maintenance injections every 3–6 months are typically recommended as hair loss is a progressive process that PRP can slow but not permanently halt.

Wound care follow-up: Wound dimensions (length × width × depth) and area should be documented at each dressing change. Percentage wound area reduction at 4 weeks predicts likelihood of complete healing — a reduction below 40% at 4 weeks is associated with failure to heal by 12 weeks in diabetic ulcers. Absence of progression or wound deterioration should prompt reassessment of diagnosis (ischaemia, osteomyelitis, vasculitis).

Laboratory monitoring: No specific blood tests are required during or after PRP treatment. Patients on anticoagulants or with thrombocytopenia may benefit from a pre-treatment FBC and platelet function assessment to ensure adequate PRP quality. Athletes on WADA-governed programmes should document TUE compliance.

PRP therapy is predominantly self-funded in most healthcare systems, as it is not covered under standard insurance in the UK (NHS), most European public health systems, or Medicare/Medicaid in the United States for most indications. Understanding costs is essential for informed consent.

Per-session costs: A single PRP injection session typically costs £300–£600 in the UK, $500–$1,500 USD in the United States, and INR 5,000–15,000 in India depending on the clinic, preparation system, guided injection, and indication. Costs vary significantly between a basic physician-administered injection and an ultrasound-guided injection at a sports medicine centre.

Total treatment courses: Most indications require 2–3 sessions (knee OA, tendinopathy) or 3 monthly sessions followed by quarterly maintenance (hair loss). Total course costs therefore range from £600–£1,800 (UK) to $1,500–$4,500 USD for a standard musculoskeletal course. Hair loss maintenance (4 sessions per year indefinitely) adds ongoing annual expense of £1,200–£2,400.

Factors that increase cost:

• Ultrasound or fluoroscopic guidance for precision injection (adds £100–£300 per session)
• FDA-cleared commercial PRP preparation kits (Arthrex ACP, Regen Lab) cost more than manual centrifugation but provide more consistent platelet concentrations
• Private specialist clinics (sports medicine consultants, dermatologists) versus GP or physiotherapy-led services
• Geographic location — London, New York, Dubai, and Singapore commands higher fees than regional centres

Insurance landscape: In the United States, Medicare covers PRP for chronic non-healing diabetic foot ulcers (specific CPT billing codes), making this the one PRP indication with reimbursement support. Musculoskeletal and hair loss PRP are consistently non-reimbursed. Some private health insurers are beginning to cover PRP for specific tendinopathies, particularly in sports medicine coverage riders.

Cost-effectiveness: For knee OA, PRP is not currently endorsed by NICE in the UK as cost-effective over HA or physiotherapy. Cost-effectiveness modelling is limited by preparation heterogeneity and variable trial quality, underscoring the need for standardised large RCTs before widespread public funding.

Several established alternatives to PRP exist for the major indications where PRP is used, and shared decision-making should incorporate a balanced comparison of evidence, cost, and patient preferences.

Knee Osteoarthritis alternatives:

• Hyaluronic acid (HA) injections: Viscosupplementation with sodium hyaluronate remains commonly used. The RESTORE trial showed equivalence to PRP at 12 months. Multiple branded products (Synvisc, Euflexxa, Durolane) are available. HA is sometimes insurance-covered where PRP is not.
• Corticosteroid injections: Provide faster short-term pain relief than PRP but effects wane by 3 months. Repeated injections may accelerate cartilage degradation — generally limited to 3–4 per year.
• Total knee replacement (TKR): For end-stage OA (KL grade IV) with severe functional limitation, TKR remains the gold-standard definitive intervention with high satisfaction rates (>90% at 10 years).

Tendinopathy alternatives:

• Eccentric exercise programmes: Structured eccentric loading (Alfredson protocol for Achilles, Tyler Twist for lateral epicondylitis) remains a first-line evidence-based approach. Low cost, high evidence, no injection required.
• Shockwave therapy (ESWT): Extracorporeal shockwave therapy has comparable efficacy to PRP for lateral epicondylitis and patellar tendinopathy in several RCTs, with some meta-analyses showing marginal PRP superiority. ESWT is non-invasive.
• High-volume injection: For Achilles tendinopathy, high-volume injection (40 mL saline + corticosteroid) disrupts neovascularisation and provides medium-term benefit comparable to PRP in some studies.

Hair loss alternatives:

• Minoxidil 5% topical: Licensed, inexpensive, and effective first-line agent that slows hair loss and promotes regrowth in androgenetic alopecia. Less dramatic than PRP but substantially cheaper.
• Finasteride (men) or dutasteride: Oral 5-alpha reductase inhibitors reduce DHT-mediated follicular miniaturisation. Highly effective but require indefinite use and carry sexual side effects in a minority.
• Hair transplant surgery (FUE/FUT): Permanent restoration for moderate-to-advanced alopecia, though costly ($4,000–$15,000 USD) and limited by donor hair availability. PRP is sometimes used alongside transplant to improve graft survival.